MANUFACTURING ACCREDITATIONS  
Accreditations ISO 9001:2015
ISO 13485:2003
EN ISO 13485:2012
CHEMOTHERAPY DRUGS AND CONCENTRATION
(TESTED FOR RESISTANCE TO PERMEATION BY CHEMOTHERAPY DRUGS AS PER ASTM D6978-05, TEST REPORT PN 104145A)
MINIMUM BREAKTHROUGH DETECTION TIME (MINUTES)
Carmustine (BCNU), 3.3mg/ml (3,300ppm) 1.2
Cisplatin, 1.0mg/ml (1,000ppm) >240
Cyclophosphamide (Cytoxan), 20.0mg/ml (20,000ppm) >240
Dacarbazine (DTIC), 10.0mg/ml (10,000ppm) >240
Doxorubicin Hydrochloride, 2.0mg/ml (2,000ppm) >240
Etoposide (Toposar), 20.0mg/ml (20,000ppm) >240
Fluorouracil, 50.0mg/ml (50,000ppm) >240
Methotrexate, 25.0mg/ml (25,000ppm) >240
Mitomycin C, 0.5mg/ml (500ppm) >240
Paclitaxel (Taxol), 6.0mg/ml (6,000ppm) >240
Thiotepa, 10.0mg/ml (10,000ppm) 30.9
Vincristine Sulfate, 1.0mg/ml (1,000ppm) >240
WARNING: Carmustine and Thiotepa, at the tested concentration, degraded a Celeste nitrile glove at 1.2 minutes and 30.9 minutes respectively. The safe use of gloves in chemotherapy treatment is solely the decision of clinicians authorised to make such a decision.

(661)